Point-of-care biosensors and microfluidics in 2026: overview
Point-of-care biosensors combine biological recognition with a signal readout, while microfluidics controls small volumes of fluid for sampling, preparation and analysis. Together, they can bring diagnostic results closer to patients and reduce reliance on centralized laboratory workflows. The field is balancing more sensitive detection with practical demands: simple sample handling, reliable results across real-world samples, and devices that are straightforward to manufacture and use. Publications rose 17.6% while patent activity fell 35.1% in the latest year-over-year comparison.
Recent work is pushing toward integrated, multiplexed testing and monitoring beyond clinics. In August 2026, studies combined CRISPR-Cas12 with microfluidic chips to detect respiratory pathogens and developed a centrifugal microfluidic platform for multiplex testing. Other directions include wearable microfluidics for reproductive-hormone monitoring, fluorescence readout across multichannel chips, and dry-chemistry workflows. These designs address persistent engineering challenges: preparing complex samples, maintaining sensitivity without bulky equipment, and making results robust enough for clinical decisions.
- 1More targets, one test: CRISPR assays paired with microfluidic chips are moving toward multiplex pathogen detection, but sensitivity, throughput and workflow simplicity remain competing design goals.
- 2Sensing moves closer: Wearable hormone monitoring and saliva-based periodontal sensing extend point-of-care testing toward continuous or routine sampling outside conventional clinical settings.
- 3Different signals, same hurdle: Optical, electrochemical and lateral-flow methods offer distinct readouts, while all must manage sample variation and deliver dependable results in compact formats.
Top organizations working on point-of-care biosensors and microfluidics
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to point-of-care biosensors and microfluidics. Showing 7 of 3,000 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
Siemens AG
Corporate · Germany |
General | PUB 1 · NEWS 985 | -71% | Siemens Healthineers supplies point-of-care diagnostic analyzers and assays for clinical settings, bringing laboratory testing closer to patients. |
| 2 | 
Abbott Laboratories
Corporate · United States |
Electrochemical biosensors | PUB 2 · NEWS 776 | -56% | Its point-of-care portfolio includes glucose monitoring and rapid diagnostic assays, enabling testing and ongoing measurement outside centralized laboratories. |
| 3 | 
Thermo Fisher Scientific
Corporate · United States |
General | PUB 5 · NEWS 906 | -56% | Thermo Fisher supplies diagnostic instruments, assays, and molecular testing products that support decentralized testing, alongside its broader laboratory-science portfolio. |
| 4 | 
Roche Diagnostics
Corporate · United States |
Microfluidic lab-on-chip platforms | PUB 2 · NEWS 530 | -81% | Roche Diagnostics develops clinical diagnostic systems and assays, including compact molecular testing platforms and lateral-flow tests for near-patient use. |
| 5 | 
Hoffmann-La Roche
Corporate · Switzerland |
General | PUB 7 · NEWS 407 | -47% | Roche develops diagnostic assays and instruments for clinical laboratories and near-patient testing, including molecular and rapid-test platforms. |
| 6 | 
Danaher Life Science
Corporate · United States |
Nucleic-acid amplification | NEWS 335 | -59% | Through diagnostics businesses including Cepheid, Danaher supplies molecular testing systems used for rapid infectious-disease testing near the point of care. |
| 7 | 
Bio Rad Laboratories Inc.
Corporate · United States |
General | NEWS 441 | -54% | Bio-Rad develops clinical diagnostic instruments and assays, including infectious-disease and molecular testing products used in healthcare laboratories. |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Startups to watch and leading research centers
Startups to watch 31 total
Atantares CorporationUnited StatesAtantares is developing biochip-based diagnostics; its associated work integrates microfluidics and electrode aggregometry for point-of-care platelet-function analysis.
Genspeed Biotech GmbhAustriaGenspeed develops rapid in-house pathogen testing; its work includes translating foil-based lateral-flow chips toward scalable production.- GSGRAPHENEA SEMICONDUCTORGraphenea Semiconductor is associated with graphene-based sensing research, including field-effect biosensors for detecting neurological biomarkers in blood.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
Leading research institutions 2,656 total
Chinese Academy of Sciences CASChinaRecently, researchers associated with the academy reported a pumpless microfluidic chip for point-of-care coagulation monitoring and a portable platform for DNA extraction and multiplex pathogen detection.
Centers for Disease Control and PreventionUnited StatesCDC research includes a label-free optical biosensor approach for rapid point-of-care detection of monkeypox virus.
University of CaliforniaUnited StatesRecently, University of California researchers evaluated point-of-care capillary hemoglobin testing in trauma care; its research also spans packaged microfluidic analyzers and PCR chips.- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where point-of-care biosensors and microfluidics innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 3,000 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Lateral-flow immunoassays | Lateral-flow immunoassays use capillary flow and visible or instrument-read signals for simple testing, but sensitivity and quantitative precision can be limiting. | 476 |
Siemens AG, Abbott Laboratories, Thermo Fisher Scientific |
| Electrochemical biosensors | Electrochemical biosensors convert recognition events into electrical signals and can support compact readers, but electrode stability and sample interference require control. | 534 |
Guangzhou Medical University, Shandong University, Chinese Academy of Sciences CAS |
| Optical biosensors | Optical biosensors measure changes in light to detect targets, offering flexible signal strategies but often needing careful control of optics and background. | 2,432 |
Siemens AG, Chinese Academy of Sciences CAS, Abbott Laboratories |
| Nucleic-acid amplification | Nucleic-acid amplification increases target genetic material for detection, supporting sensitive pathogen testing but adding reaction and temperature-control steps. | 1,095 |
Siemens AG, Thermo Fisher Scientific, Abbott Laboratories |
| Microfluidic lab-on-chip platforms | Lab-on-chip platforms integrate fluid handling and assay steps in small devices, but reliable sample preparation and scalable manufacturing remain challenging. | 492 |
Thermo Fisher Scientific, Abbott Laboratories, Siemens AG |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
Funding data records $274.7 million across 313 grants since 2020, alongside 23 funding rounds totaling about $1.57 billion.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Oct 2026Wilmington, DE, United States, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Point-of-Care Diagnostics Emerging as one of the Most Strategically Controlled Layers of Modern Healthcare Delivery Diagnostic testing has spent decades…GlobeNewswire - Research Analysis And Reports
- Sep 2026Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- "Mexico Biosensors Market Size, Share, Trends and Forecast by Product, Technology, Application, End Use, and Region, 2026-2034" has been added to ResearchAndMarkets.com's…GlobeNewswire - Research Analysis And Reports
- Sep 2026Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- "Microfluidics Market Insights, Competitive Landscape, and Market Forecast - 2033" has been added to ResearchAndMarkets.com's offering. The global microfluidics market is…GlobeNewswire - Research Analysis And Reports
- Jul 2026NEW YORK, USA, July 14, 2026 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Point-Of-Care Molecular Diagnostics Market By Product Type (Instruments and Analyzers, Reagents and…GlobeNewswire: Industry News on Business Support Services
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about point-of-care biosensors and microfluidics
What companies are working on point-of-care biosensors and microfluidics?
Siemens AG, Abbott Laboratories and Thermo Fisher Scientific are among the prominent companies active in this field. Their work spans point-of-care diagnostic analyzers, glucose monitoring, rapid assays, instruments and molecular testing products. Roche Diagnostics, Hoffmann-La Roche and Danaher Life Science also supply diagnostic systems or assays used in near-patient testing.
Which startups are working on point-of-care biosensors and microfluidics?
Atantares Corporation, Genspeed Biotech GmbH and GRAPHENEA SEMICONDUCTOR are identified as startups working in this area. Atantares is associated with biochip-based platelet-function analysis; Genspeed works on rapid pathogen testing and foil-based lateral-flow chips; GRAPHENEA SEMICONDUCTOR is associated with graphene-based sensing research, including field-effect biosensors.
Which universities and research centers lead point-of-care biosensors and microfluidics research?
The Chinese Academy of Sciences CAS is a prominent research organization, with work on a pumpless coagulation-monitoring chip and portable DNA extraction and pathogen detection. The Centers for Disease Control and Prevention and the University of California also appear among leading research organizations, with work on optical virus detection and point-of-care hemoglobin testing, respectively.
How much funding has point-of-care biosensors and microfluidics received?
Funding data records $274.7 million across 313 grants since 2020, plus 23 funding rounds totaling about $1.57 billion. These figures represent the funding recorded for the topic, rather than a single program or a guarantee that every award is dedicated exclusively to point-of-care biosensors and microfluidics.
Who holds the most point-of-care biosensors and microfluidics patents?
Robert Bosch GmbH leads the listed patent holders with 5 patents in the window. Not Binary Ltd and Iowa State University Research Foundation have 3 each. The Regents of the University of California, Aviana Molecular Technologies LLC, Hyperfine and Abbott Point of Care each have 2 listed patents.
Is point-of-care biosensors and microfluidics patent activity growing?
No: patent activity fell 35.1% in the latest 12-month period compared with the previous 12 months. The data lists 94 patents in the 24-month window. Publication activity moved in the opposite direction, rising 17.6% in the latest year-over-year comparison, suggesting sustained research output alongside weaker recent patent activity.
What are the latest developments in point-of-care biosensors and microfluidics?
Recent directions include CRISPR-Cas12 combined with microfluidic chips for multiplex respiratory-pathogen diagnosis and an integrated centrifugal microfluidic platform for multiplex testing. August 2026 publications also describe wearable microfluidics for reproductive-hormone monitoring, multichannel fluorescence interrogation and dry-chemistry approaches. These designs target faster, more portable testing while addressing sample preparation and reliable readout.
What are the applications of point-of-care biosensors and microfluidics?
The application areas include infectious disease testing, diabetes and metabolic monitoring, cardiovascular and emergency care, cancer and oncology, and home and self-testing. The data also highlights research on neurological biomarkers, reproductive hormones, periodontal disease and foodborne pathogens, showing how near-patient testing can extend across clinical, home and food-production settings.
What are the main approaches in point-of-care biosensors and microfluidics, and how do they differ?
The main approaches are lateral-flow immunoassays, electrochemical biosensors, optical biosensors, nucleic-acid amplification and microfluidic lab-on-chip platforms. They differ in how they recognize targets and produce a signal: lateral flow uses capillary movement, electrochemical and optical sensors read signal changes, amplification detects genetic material, and lab-on-chip systems integrate fluid-handling steps.